TXG Key Statistics, Chart & Performance
The current stock price of TXG is 22.47 USD. In the past month the price increased by 35.64%. In the past year, price increased by 51.11%.
TXG Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TXG. When comparing the yearly performance of all stocks, TXG is one of the better performing stocks in the market, outperforming 93.63% of all stocks.
TXG Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TXG. While TXG has a great health rating, there are worries on its profitability.
TXG Financial Highlights
Over the last trailing twelve months TXG reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS increased by 54.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.43% | ||
| ROE | -9.72% | ||
| Debt/Equity | 0 |
TXG Forecast & Estimates
22 analysts have analysed TXG and the average price target is 18.16 USD. This implies a price decrease of -19.2% is expected in the next year compared to the current price of 22.47.
For the next year, analysts expect an EPS growth of 68.46% and a revenue growth 4.85% for TXG
TXG Ownership
About TXG
Company Profile
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,306 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Company Info
10X GENOMICS INC-CLASS A
6230 Stoneridge Mall Road
Pleasanton CALIFORNIA 94588 US
CEO: Serge Saxonov
Employees: 1306
Phone: 19254017300
10X GENOMICS INC-CLASS A / TXG FAQ
Can you describe the business of 10X GENOMICS INC-CLASS A?
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,306 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
What is the stock price of 10X GENOMICS INC-CLASS A today?
The current stock price of TXG is 22.47 USD. The price increased by 0.4% in the last trading session.
What is the dividend status of 10X GENOMICS INC-CLASS A?
TXG does not pay a dividend.
What is the ChartMill technical and fundamental rating of TXG stock?
TXG has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists TXG stock?
TXG stock is listed on the Nasdaq exchange.
What do analysts say about 10X GENOMICS INC-CLASS A (TXG) stock?
22 analysts have analysed TXG and the average price target is 18.16 USD. This implies a price decrease of -19.2% is expected in the next year compared to the current price of 22.47.
What is the employee count for TXG stock?
10X GENOMICS INC-CLASS A (TXG) currently has 1306 employees.